دورية أكاديمية
أعرض في EDS

The Prevalence and Antimicrobial Susceptibility of Methicillin-Resistant Staphylococcus aureus Before and After the COVID-19 Pandemic in a Tertiary Saudi Hospital.

التفاصيل البيبلوغرافية
العنوان: The Prevalence and Antimicrobial Susceptibility of Methicillin-Resistant Staphylococcus aureus Before and After the COVID-19 Pandemic in a Tertiary Saudi Hospital.
المؤلفون: Ahmed OB; Environmental and Health Research, Umm Al-Qura University, Makkah, SAU., Bahwerth FS; Laboratory, King Faisal Hospital, Makkah, SAU., Alsafi R; Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, SAU., Elsebaei EA; Medical Microbiology, Egypt Healthcare Authority, Cairo, EGY., Ebid GT; Laboratory Medicine, Security Forces Hospital, Makkah, Makkah, SAU.; National Cancer Institute, Cairo University, Cairo, EGY., Theyab A; Department of Laboratory and Blood Bank, Security Forces Hospital, Mecca, Makkah, SAU.; Collage of Medicine, Al-Faisal University, Riyadh, SAU., Assaggaf H; Laboratory Medicine/Public Health, Umm Al-Qura University, Makkah, SAU.
المصدر: Cureus [Cureus] 2024 Feb 24; Vol. 16 (2), pp. e54809. Date of Electronic Publication: 2024 Feb 24 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Background: Methicillin-resistant Staphylococcus  aureus (MRSA) has become a major public health problem all over the world. After the 2019 coronavirus illness (COVID-19), the pandemic may have influenced research priorities and resource allocation, potentially affecting the ability to monitor MRSA trends.
Aims: The study aimed to evaluate the prevalence of S. aureus, including MRSA infections, and their antimicrobial susceptibilities over the years 2019 and 2020 in a tertiary hospital in Makkah City, KSA.
Methodology: A total of 2128 and 1515 laboratory (lab) samples were collected during the years 2019 and 2020, respectively. From these samples, the prevalence of S. aureus, including MRSA, and their antibiotic susceptibility were identified using standard, automated, and molecular microbiological methods.
Results: The present study shows that the lab prevalence of all S. aureus during 2019 was found to be 35.5%, of which MRSA was 44.8%. During 2020, the frequency of S. aureus strains was 16%, of which MRSA was 41.2%. The most common MRSA isolated during both years were colonizing pus swabs and urine samples. The results showed that MRSA susceptibility against antimicrobial agents in 2019 was as follows: vancomycin (100%), linezolid (100%), trimethoprim-sulfamethoxazole (88%), and doxycycline (34.2%). The MRSA strains isolated during 2020 were as follows: vancomycin (100%), linezolid (96%), trimethoprim-sulfamethoxazole (100%), and doxycycline (24.3%). There was no significant difference in the incidence and antimicrobial resistance rates of MRSA over the two years.
Conclusion: It was concluded that the prevalence rates of MRSA have not increased in 2020 when compared to 2019. Vancomycin, linezolid, trimethoprim-sulfamethoxazole, and doxycycline remain susceptible to the positive collected MRSA strains. There was no significant difference between the prevalence and antimicrobial resistance rates of MRSA between 2019 and 2020. Continued research efforts are needed to address this persistent public health threat. Strategies to control the spread of MRSA should include early detection of MRSA and surveillance, even during pandemics.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2024, Ahmed et al.)
References: Front Microbiol. 2021 Apr 30;12:668900. (PMID: 33995333)
MMWR Morb Mortal Wkly Rep. 2019 Mar 08;68(9):220-224. (PMID: 30845116)
J Hosp Infect. 1994 Apr;26(4):297-300. (PMID: 7915291)
Antibiotics (Basel). 2022 Apr 29;11(5):. (PMID: 35625250)
Cureus. 2020 Dec 25;12(12):e12289. (PMID: 33391963)
Cell Microbiol. 2015 Mar;17(3):303-17. (PMID: 25293394)
Expert Opin Pharmacother. 2023 Feb;24(3):331-346. (PMID: 36548447)
Infect Control Hosp Epidemiol. 2021 Sep;42(9):1156-1158. (PMID: 32843125)
Br J Biomed Sci. 2011;68(4):171-3. (PMID: 22263429)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
JAC Antimicrob Resist. 2021 Apr 08;3(2):dlab038. (PMID: 34192258)
J Infect Dev Ctries. 2022 Sep 30;16(9):1450-1457. (PMID: 36223621)
Cureus. 2021 May 10;13(5):e14934. (PMID: 34123631)
Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
Ital J Pediatr. 2022 May 7;48(1):67. (PMID: 35526042)
Clin Microbiol Infect. 2023 Mar;29(3):302-309. (PMID: 36509377)
Saudi J Med Med Sci. 2016 Jan-Apr;4(1):2-8. (PMID: 30787687)
Can J Microbiol. 2007 Aug;53(8):931-6. (PMID: 17898849)
Biofabrication. 2020 Feb 19;12(2):025012. (PMID: 31994489)
N Engl J Med. 2005 Apr 7;352(14):1485-7. (PMID: 15814886)
Int J Health Sci (Qassim). 2020 Jan-Feb;14(1):9-19. (PMID: 31983916)
Saudi Med J. 2003 Dec;24(12):1313-6. (PMID: 14710275)
JAMA. 2013 Jan 16;309(3):275-82. (PMID: 23321766)
J Infect Dis. 2011 Mar 15;203(6):880-8. (PMID: 21278211)
BMC Infect Dis. 2017 Apr 13;17(1):274. (PMID: 28407796)
فهرسة مساهمة: Keywords: covid-19; makkah; mrsa; mssa; s. aureus
تواريخ الأحداث: Date Created: 20240326 Latest Revision: 20240327
رمز التحديث: 20240327
مُعرف محوري في PubMed: PMC10962010
DOI: 10.7759/cureus.54809
PMID: 38529437
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.54809